Biofourmis, a fast-growing AI-based remote monitoring technology, and digital therapeutics have raised a $100 million Series C funding round. The venture was led by SoftBank Vision Fund 2, with participation from existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital, and EDBI.
Biofourmis will use this funding to accelerate its global expansion, advance digital therapeutics pipeline, develop additional care pathways, and drive deeper integration with the health system, hospital, pharmaceutical, and clinical research clients and partners. In addition, Biofourmis will use the funding for developing, validating, and commercializing several released and unreleased digital therapeutics solutions across cardiology, respiratory, oncology and pain. The company plans to focus on the United States and key Asian markets, including the Asia Pacific, China, and Japan.